Related Experiment Videos
Inhaled diazeniumdiolates (NONOates) as selective pulmonary vasodilators
Chen-Fuh Lam1, Sigal Sviri, Kenneth F Ilett
1Department of Pharmacology, University of Western Australia, Crawley, WA 6009, Australia. cflam@cyllene.uwa.edu.au
Expert Opinion on Investigational Drugs
|June 27, 2002
Summary
Inhaled NONOates offer targeted pulmonary vasodilation, improving lung perfusion with minimal systemic effects. This review explores their potential for treating pulmonary hypertension, right ventricular dysfunction, and asthma.
Area of Science:
- Pharmacology
- Pulmonary Medicine
- Respiratory Physiology
Background:
- Selective pulmonary vasodilators target lung vasculature, improving ventilation/perfusion matching.
- Nitric oxide (NO) is a potent pulmonary vasodilator but has limitations.
- NONOates are novel compounds releasing NO continuously for up to 24 hours.
Purpose of the Study:
- To review the therapeutic potential of inhaled NONOates.
- To explore their application in pulmonary hypertension, right ventricular dysfunction, and asthma.
- To discuss the potential toxicity of NONOates.
Main Methods:
- Literature review of inhaled NONOates.
- Analysis of NONOate properties and NO release mechanisms.
- Evaluation of existing research on NONOates in respiratory conditions.
Main Results:
- Inhaled NONOates provide sustained NO release, mimicking gaseous NO benefits.
- They offer targeted vasodilation in well-ventilated lung regions.
- Potential applications exist for pulmonary hypertension, RV dysfunction, and asthma.
Conclusions:
- Inhaled NONOates represent a promising therapeutic strategy for various lung diseases.
- Further research is needed to fully elucidate their efficacy and safety profile.
- NONOates may overcome limitations associated with traditional NO therapy.